A recent pilot study has revealed that liver screening at health clinics can prevent liver diseases. It shares that the best path for addressing liver disease is to identify the issue early on and make lifestyle changes accordingly.
A study testing on-site liver screening at a community health clinic was led by researchers at Brown’s Center for Alcohol and Addiction Studies in partnership with Clínica Esperanza in Providence.
(Source: Nick Dentamaro)
Rhode Island/USA – People from groups most affected by liver disease are often unaware of their diagnosis until it has already reached an advanced stage.
To preempt that challenge, researchers from the Brown University School of Public Health conducted a study that screened patients for liver disease and associated risk factors during visits to a community health clinic, and then offered various forms of counseling. The pilot study, which included 14 people, identified three participants with liver stiffness and eight with liver disease, and provided patients with the opportunity to reverse the damage they didn’t realize they had.
The study was published in Rhode Island Medical Journal and led by Hayley Treloar Padovano and Mollie Monnig, psychologists affiliated with Brown’s Center for Alcohol and Addiction Studies. Treloar Padovano, who holds associate professor roles at Brown’s School of Public Health and Warren Alpert Medical School, says the best path for addressing liver disease is to identify the issues early and change behavior around alcohol use and diet.
“One of the biggest factors causing disparities in who progresses to the most severe liver disease and then eventually dies waiting on transplant lists is they were not diagnosed early enough and never offered appropriate treatment,” Treloar Padovano said.
Steatotic liver disease, which involves an accumulation of excess fat in the liver, can lead to inflammation and damage and is often linked to metabolic issues like obesity, diabetes and high cholesterol, as well as alcohol use.
Liver disease is preventable with lifestyle modifications, the authors said. But associated risks like obesity and diabetes are on the rise, and without intervention, deaths caused by chronic liver disease will double by 2040, with populations experiencing health disparities hit the hardest.
“There is a critical, unmet need for integrated interventions that are culturally relevant and delivered through existing community health care systems to reduce disparities via early disease detection and connection to life-saving care,” Treloar Padovano said.
On-site screening for an often invisible health issue
To conduct the study, the team partnered with Clínica Esperanza, a nonprofit clinic that provides high-quality, culturally and language-attuned health care to uninsured adults in Rhode Island.
Over 11 months, the study involved a two-stage screening process, incorporated into the clinic’s onboarding process, to target adults over the age of 21 with multiple health risk factors. The researchers reviewed electronic health records to identify patients with body mass index of 25+ and who scored at-risk on a test assessing alcohol use disorder. Adults who met the criteria received behavioral screening at the clinic as well as diagnostic imaging using a Fibroscan device that detects liver stiffness and fat accumulation.
Preliminary pilot data identified liver stiffness (fibrosis) in 21 % of participants and steatosis in 57 %. None of the identified patients had been previously aware of their condition.
A psychologist on the study team met with participants, who were randomly selected to receive either brief advice or a type of counseling referred to as motivational interviewing, to discuss their risk factors for liver disease. Participants were connected to resources such as clinic programs that promote substance use reduction and cardiometabolic health, and patients with significant Fibroscan findings had results provided to their health care team.
A key finding of the study was that providing personalized feedback from clinic diagnostics can reduce biobehavioral risk factors and prevent the progression of liver damage to advanced disease, said Monnig, an associate professor of behavioral and social sciences at Brown.
“Although the intervention lasted only 30 days, the qualitative feedback from patients was very strong,” Monnig said. “Many expressed surprise at the condition and gratitude for feeling empowered to do something about it.”
The researchers concluded that integrating on-site diagnostics with culturally attuned behavioral interventions in a community-centric clinic can bypass traditional barriers to care and detect "silent" liver disease at treatable stages.
“Patient exit interviews from our small study showed that even with a brief intervention, you can really change people’s perspectives and behavior to help them lower their risk of liver disease,” Treloar
Date: 08.12.2025
Naturally, we always handle your personal data responsibly. Any personal data we receive from you is processed in accordance with applicable data protection legislation. For detailed information please see our privacy policy.
Consent to the use of data for promotional purposes
I hereby consent to Vogel Communications Group GmbH & Co. KG, Max-Planck-Str. 7-9, 97082 Würzburg including any affiliated companies according to §§ 15 et seq. AktG (hereafter: Vogel Communications Group) using my e-mail address to send editorial newsletters. A list of all affiliated companies can be found here
Newsletter content may include all products and services of any companies mentioned above, including for example specialist journals and books, events and fairs as well as event-related products and services, print and digital media offers and services such as additional (editorial) newsletters, raffles, lead campaigns, market research both online and offline, specialist webportals and e-learning offers. In case my personal telephone number has also been collected, it may be used for offers of aforementioned products, for services of the companies mentioned above, and market research purposes.
Additionally, my consent also includes the processing of my email address and telephone number for data matching for marketing purposes with select advertising partners such as LinkedIn, Google, and Meta. For this, Vogel Communications Group may transmit said data in hashed form to the advertising partners who then use said data to determine whether I am also a member of the mentioned advertising partner portals. Vogel Communications Group uses this feature for the purposes of re-targeting (up-selling, cross-selling, and customer loyalty), generating so-called look-alike audiences for acquisition of new customers, and as basis for exclusion for on-going advertising campaigns. Further information can be found in section “data matching for marketing purposes”.
In case I access protected data on Internet portals of Vogel Communications Group including any affiliated companies according to §§ 15 et seq. AktG, I need to provide further data in order to register for the access to such content. In return for this free access to editorial content, my data may be used in accordance with this consent for the purposes stated here. This does not apply to data matching for marketing purposes.
Right of revocation
I understand that I can revoke my consent at will. My revocation does not change the lawfulness of data processing that was conducted based on my consent leading up to my revocation. One option to declare my revocation is to use the contact form found at https://contact.vogel.de. In case I no longer wish to receive certain newsletters, I have subscribed to, I can also click on the unsubscribe link included at the end of a newsletter. Further information regarding my right of revocation and the implementation of it as well as the consequences of my revocation can be found in the data protection declaration, section editorial newsletter.
Padovano said.
The researchers are applying for funding to conduct a randomized control trial to assess the program’s effectiveness on a larger scale.
The project was funded by the National Institutes of Health as a Team Science supplement to the Center for Addiction and Disease Risk Exacerbation at Brown’s School of Public Health. The research team also included Dr. Kittichai Promrat, a gastroenterologist and hepatologist with Brown University Health’s Center for Inflammatory Bowel and Liver Disease, and Stephanie Goldstein, an associate professor of psychiatry and human behavior (research) at Brown.